Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.51 |
| ▸ | PARP1 | P09874 | 1/20 | 0.46 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.45 |
| ▸ | FUBP1 | Q96AE4 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.40 |
| ▸ | DPP4 | P27487 | 1/20 | 0.39 |
| ▸ | CDK4 | P11802 | 1/20 | 0.39 |
| ▸ | CCND1 | P24385 | 1/20 | 0.39 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5457663 | 0.81 | NPC1 (0.52) | PARP1MEN1ALDH1A1KMT2AL3MBTL1 | |
| SCHEMBL18788145 | 0.76 | GRM2 (0.46) | ALDH1A1ABCG2 | |
| SCHEMBL18788152 | 0.73 | USP2 (0.57) | ALDH1A1KMT2A | |
| SCHEMBL24693472 | 0.73 | USP2 (0.40) | ALDH1A1 | |
| SCHEMBL23998420 | 0.72 | ABCB1 (0.49) | ADORA3ABCB1FUBP1MEN1ALDH1A1 | |
| SCHEMBL23998523 | 0.69 | PARP1 (0.58) | ADORA3PARP1MEN1ALDH1A1KMT2A | |
| SCHEMBL23447727 | 0.68 | ALDH1A1 (0.63) | ABCB1MEN1ALDH1A1ALOX15KMT2A | |
| SCHEMBL13815718 | 0.67 | DPP4 (0.49) | ABCB1FUBP1MEN1ALDH1A1ALOX15 | |
| SCHEMBL11245104 | 0.66 | ALDH1A1 (0.34) | MEN1ALDH1A1ALOX15KMT2AL3MBTL1 | |
| SCHEMBL23998222 | 0.66 | ALDH1A1 (0.43) | ADORA3ABCB1MEN1ALDH1A1ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122010947-A | Antagonists of adenosine A2a receptors | 阿道尔克斯治疗有限公司 | 2026-05-12 | — | — | CN | disclosed |
| US-20230203041-A1 | ANTAGONISTS OF THE ADENOSINE A2A RECEPTOR | JANSSEN PHARMACEUTICA NV (BE) | 2023-06-29 | — | — | US | disclosed |
| US-20230203041-A1 | ANTAGONISTS OF THE ADENOSINE A2A RECEPTOR | JANSSEN PHARMACEUTICA NV (BE) | 2023-06-29 | — | — | US | disclosed |
| CN-115996929-A | Antagonists of adenosine A2a receptors | 阿道尔克斯治疗有限公司 | 2023-04-21 | — | — | CN | disclosed |
| WO-2021224636-A1 | ANTAGONISTS OF THE ADENOSINE A2A RECEPTOR | AdoRx Therapeutics Limited (GB) | 2021-11-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230203041-A1 | ANTAGONISTS OF THE ADENOSINE A2A RECEPTOR | ADORA2A, ADORA1, ADORA3 | ADORA3 3/4885PARP1 522/4885ABCB1 174/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.